A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Open to people ages 18 years and up

• Previously untreated with histological confirmation of AML by World Health Organization 2022 criteria and are ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age, or comorbidity.
• Participant has any level of CD123 expression on blasts confirmed centrally by flow cytometry.
• Must be considered ineligible for intensive chemotherapy, defined by the following:
  • ≥75 years of age; or
  • ≥18 to 74 years of age with at least 1 of the following comorbidities:
    • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or 3.
    • Diffusing capacity of the lung for carbon monoxide of ≤65% or forced expiratory volume in 1 second ≤65%.
    • Baseline creatinine clearance ≥30 to <45 milliliters/minute calculated by the Cockcroft Gault formula or measured by 24-hour urine collection.
    • Hepatic disorder with total bilirubin >1.5 x upper limit of normal.
    • Any other comorbidity that the investigator judges to be incompatible with intensive chemotherapy must be reviewed and approved by the Sponsor.
• ECOG performance status:
  • 0 to 2 for participants ≥75 years of age, or
  • 0 to 3 for participants ≥18 to 74 years of age.

• Participant has received prior therapy for AML.
• Willing and able to receive standard induction therapy.
• Treatment for an antecedent hematologic disease with a hypomethylating agent, venetoclax, tagraxofusp, purine analogue, cytarabine, intensive chemotherapy, chimeric antigen receptor-T therapy, or other experimental therapies.
• AML with central nervous system involvement.

Note: Other inclusion/exclusion criteria may apply.